# A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

> **NCT07230106** · PHASE2 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 218 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** HS-20093 for Injection
- **DRUG:** SHR3680 Tablet
- **DRUG:** Abiraterone Tablet
- **DRUG:** SHR2554 Tablet
- **DRUG:** Enzalutamide Tablet
- **DRUG:** Darotamine Capsule

## Key facts

- **NCT ID:** NCT07230106
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-08
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 218 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07230106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07230106, "A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07230106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*